Form 4: Biofrontera CFO Leffler Receives New Equity Awards

Biofrontera Inc.'s Chief Financial Officer, Eugene Frederick Leffler, received new grants of restricted stock units and stock options, alongside the conversion of previously awarded restricted stock units into common shares.

Summary

• Eugene Frederick Leffler, Chief Financial Officer of Biofrontera Inc. (BFRI), acquired 87,500 shares of common stock on March 5, 2026, through the conversion of restricted stock units.
• Following this transaction, Leffler directly beneficially owns 175,000 shares of common stock.
• On March 4, 2026, Leffler was granted 62,500 new Restricted Stock Units (RSUs) which vest in two equal yearly installments starting March 4, 2027.
• Also on March 4, 2026, Leffler received a grant of 62,500 employee stock options with an exercise price of $0.9, vesting in two equal installments on September 4, 2026, and March 4, 2027, and expiring on March 4, 2036.
• A previous grant of 175,000 RSUs on July 12, 2024, had an incorrect vesting schedule reported in a September 16, 2025, Form 4.
• Due to an administrative error, the settlement of the July 12, 2024, RSU grant was delayed, with tranches settled on September 10, 2025, and March 5, 2026, instead of the original January 12, 2025, and July 12, 2025, dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the new equity awards aligning management interests, but tempered by the administrative errors and incorrect reporting of previous grants, which could suggest minor internal control issues.

Positives

• CFO Eugene Frederick Leffler received new equity awards, including 62,500 Restricted Stock Units and 62,500 employee stock options, aligning his interests with shareholders.
• The exercise price of the new employee stock options is $0.9, indicating a potential future upside if the stock price increases above this level.
• The conversion of 87,500 restricted stock units into common stock increases the CFO's direct ownership in the company to 175,000 shares.

Negatives

• An administrative error led to delays in the settlement of a previous RSU grant, with tranches settled on September 10, 2025, and March 5, 2026, instead of the original January 12, 2025, and July 12, 2025.
• A previous Form 4 filed on September 16, 2025, incorrectly identified the vesting schedule for 175,000 restricted stock units, indicating potential internal reporting discrepancies.

Future Outlook

The vesting schedules for the newly granted restricted stock units and employee stock options indicate future equity compensation for the CFO, aligning his long-term incentives with the company's performance.

Industry Context

StockSavvy.ai notes that equity awards to key executives like the CFO are a common practice in the biotechnology and pharmaceutical industry, aiming to retain talent and incentivize performance by linking executive compensation to shareholder value creation. These awards are typical for companies seeking to align management's long-term interests with the company's strategic goals.

Related Party Transactions

• The transactions involve equity awards and conversions for the Chief Financial Officer, which are inherently related-party transactions as part of executive compensation.

Stakeholder Impact

• Shareholders: The new equity awards align the CFO's long-term interests with shareholder value creation. The increase in direct ownership by the CFO could be seen as a positive signal of confidence in the company.
• Employees: The grants reflect ongoing executive compensation practices, which can influence overall compensation strategies within the company.

Next Steps

• The newly granted restricted stock units will begin vesting on March 4, 2027, with settlement within 60 days of vesting.
• The newly granted employee stock options will begin vesting on September 4, 2026, and March 4, 2027.

Key Dates

Recommendation

The filing details routine executive compensation awards and the conversion of previously vested equity. While the new awards align the CFO's interests with shareholders, and the increase in direct ownership is a minor positive, these transactions do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change from a "hold" position. The administrative errors noted are minor and do not significantly impact the investment thesis.

Keywords

Biofrontera Inc., BFRI, SEC Form 4, insider trading, beneficial ownership, restricted stock units, stock options, equity awards, Chief Financial Officer, Eugene Frederick Leffler, stock grants, vesting schedule